Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 15/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RARG | P13631 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17912757 | 0.84 | RORC (0.65) | RORCCYP2C9PPARGRARG | |
| SCHEMBL17912699 | 0.78 | RORC (0.46) | RORCCYP2C9CDK4CDK2CYP3A4 | |
| SCHEMBL17912592 | 0.76 | RORC (0.55) | RORCCYP2C9PPARGCYP3A4CYP1A2 | |
| SCHEMBL17912628 | 0.76 | RORC (0.63) | RORCCYP2C9PPARGCYP3A4CYP1A2 | |
| SCHEMBL17912684 | 0.76 | RORC (0.48) | RORCCYP2C9CDK4CDK2PPARG | |
| SCHEMBL17912599 | 0.76 | RORC (0.54) | RORCCYP2C9CDK4CDK2CYP3A4 | |
| SCHEMBL17912672 | 0.76 | RORC (0.55) | RORCCYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL17912730 | 0.76 | RORC (0.43) | RORCCYP2C9CDK4CDK2PPARG | |
| SCHEMBL17912559 | 0.74 | RORC (0.56) | RORCCYP2C9PPARGCYP3A4CYP1A2 | |
| SCHEMBL17912571 | 0.74 | RORC (0.58) | RORCCYP2C9CYP3A4CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3242878-B1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2020-10-14 | — | — | EP | claimed |
| US-20170362225-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2017-12-21 | — | — | US | claimed |
| EP-3242878-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2017-11-15 | — | — | EP | claimed |
| WO-2016110821-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-07-14 | — | — | WO | claimed |
| EP-3242878-B1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2020-10-14 | — | — | EP | disclosed |
| US-10435402-B2 | Bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2019-10-08 | — | — | US | disclosed |
| US-20170362225-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2017-12-21 | — | — | US | disclosed |
| EP-3242878-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016110821-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362225-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | RORC, RORA, RORB | RORC 1/4885CYP2C9 298/4885CDK4 876/4885 |
| US-10435402-B2 | Bicyclic compounds, compositions and medicinal applications thereof | RORA, RORB, RORC | RORC 3/4885CYP2C9 199/4885CDK4 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.